Los Angeles Capital Management & Equity Research Inc. raised its holdings in Alkermes Plc (NASDAQ:ALKS) by 214.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,982 shares of the company’s stock after buying an additional 186,840 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned about 0.17% of Alkermes worth $9,998,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Alkermes by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 13,224,145 shares of the company’s stock valued at $561,231,000 after purchasing an additional 196,776 shares in the last quarter. Vanguard Group Inc boosted its holdings in Alkermes by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 13,224,145 shares of the company’s stock valued at $561,231,000 after purchasing an additional 196,776 shares in the last quarter. BlackRock Inc. boosted its holdings in Alkermes by 1.1% in the 4th quarter. BlackRock Inc. now owns 10,075,972 shares of the company’s stock valued at $297,341,000 after purchasing an additional 108,852 shares in the last quarter. First Trust Advisors LP boosted its holdings in Alkermes by 2.5% in the 4th quarter. First Trust Advisors LP now owns 2,250,987 shares of the company’s stock valued at $66,427,000 after purchasing an additional 54,853 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Alkermes by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 1,546,255 shares of the company’s stock valued at $45,602,000 after purchasing an additional 76,621 shares in the last quarter. Institutional investors own 97.55% of the company’s stock.
Shares of Alkermes stock traded down $0.01 during trading on Wednesday, hitting $25.04. 670,103 shares of the company were exchanged, compared to its average volume of 993,422. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.94 and a quick ratio of 2.65. Alkermes Plc has a fifty-two week low of $24.36 and a fifty-two week high of $51.70. The company has a market capitalization of $3.92 billion, a P/E ratio of -357.71 and a beta of 1.72.
Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, April 25th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.21. Alkermes had a negative return on equity of 2.08% and a negative net margin of 15.86%. The firm had revenue of $223.10 million during the quarter, compared to the consensus estimate of $218.84 million. During the same period in the previous year, the firm posted ($0.09) EPS. The company’s quarterly revenue was down .9% compared to the same quarter last year. As a group, research analysts expect that Alkermes Plc will post -0.37 EPS for the current fiscal year.
ALKS has been the topic of a number of analyst reports. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Tuesday, January 29th. ValuEngine lowered Alkermes from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. BidaskClub lowered Alkermes from a “buy” rating to a “hold” rating in a report on Friday, January 25th. Cantor Fitzgerald set a $33.00 price target on Alkermes and gave the stock a “hold” rating in a research note on Wednesday, January 23rd. Finally, Credit Suisse Group set a $28.00 price target on Alkermes and gave the stock a “sell” rating in a research note on Friday, April 26th. Six equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $40.50.
In other Alkermes news, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $33.48, for a total value of $33,480.00. Following the completion of the transaction, the director now directly owns 8,000 shares in the company, valued at approximately $267,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Joseph Gaffin sold 5,373 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $26.89, for a total value of $144,479.97. Following the completion of the transaction, the senior vice president now owns 53,923 shares of the company’s stock, valued at $1,449,989.47. The disclosure for this sale can be found here. Insiders have sold a total of 162,373 shares of company stock valued at $5,362,950 over the last 90 days. Insiders own 4.71% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Los Angeles Capital Management & Equity Research Inc. Grows Position in Alkermes Plc (NASDAQ:ALKS)” was reported by Sundance Herald and is the sole property of of Sundance Herald. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://sundanceherald.com/2019/05/22/los-angeles-capital-management-equity-research-inc-acquires-186840-shares-of-alkermes-plc-alks.html.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Recommended Story: What is channel trading?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.